SUCNR1 and metabolic dysfunction-associated steatohepatitis: This raises interesting questions about the potential use of SUCNR1 in treating liver diseases like NASH, given that, like many other receptors that inhibit lipolysis in adipose including both FFA4 and HCA2/3, SUCNR1 actions in adipose have protective effects on liver lipotoxicity (84).